Medifast (MED) Tops Q1 EPS by 3c, Offers Guidance

Medifast (NYSE: MED) reported Q1 EPS of $3.59, $0.03 better than the analyst estimate of $3.56. Revenue for the quarter came in at $417.6 million versus the consensus estimate of $402.42 million.

GUIDANCE:

Medifast sees FY2022 EPS of $14.60-$16.05, versus the consensus of $15.62. Medifast sees FY2022 revenue of $1.78-1.84 billion, versus the consensus of $1.77 billion.

For earnings history and earnings-related data on Medifast (MED) click here.

You May Also Be Interested In

• Medtronic (MDT) Tops Q1 EPS by 6c, Beats on Revenue; Offers FY27 EPS Guidance
• Why UBS thinks this European chipmaker is still undervalued despite its premium valuation
• Kustom Entertainment agrees to buy Tickets For Less operator TFL